第一范文网 - 专业文章范例文档资料分享平台

对比FDA和CFDA批准的抗癌药物列表

来源:用户分享 时间:2020-05-23 本文由义无反顾 分享 下载这篇文档 手机版
说明:文章内容仅供预览,部分内容可能不全,需要完整文档或者需要复制内容,请下载word后使用。下载word有问题请添加微信号:xxxxxx或QQ:xxxxxx 处理(尽可能给您提供完整文档),感谢您的支持与谅解。

?

对比FDA和CFDA批准的抗癌药物列表。

?

发现事实。下面的都是FDA批准的靶点药,而有中文名称的是CFDA允许在国内销售的。

可以说,国内病人基本享受不到自从05年以来的绝大多数抗癌研究成果。为父亲大人学习相关知识。

AgentTarget(s)FDA-approved indication(s)CFDA approved

Ado-trastuzumab emtansine

HER2 (ERBB2/neu)

(Kadcyla)

EGFR (HER1/ERBB1), HER2

Afatinib (Gilotrif)

(ERBB2/neu)

Aldesleukin (Proleukin)

Alemtuzumab (Campath) Axitinib (Inlyta) Belimumab (Benlysta) Belinostat (Beleodaq) Bevacizumab (Avastin)

Bortezomib (Velcade) [1] |

2014-12-30 11:28jastee

CD52

KIT, PDGFRβ, VEGFR1/2/3 BAFF HDAC VEGF ligand Proteasome

21 substitution (L858R) mutations) Renal cell carcinoma Melanoma

B-cell chronic lymphocytic leukemia Renal cell carcinoma Lupus erythematosus Peripheral T-cell lymphoma Cervical cancer

注射液

Colorectal cancer Fallopian tube cancer Glioblastoma

Non-small cell lung cancer Ovarian cancer Peritoneal cancer Renal cell carcinoma Multiple myeloma

佐米 注射用硼替 贝伐珠单抗

Non-small cell lung cancer (with EGFR exon 19 deletions or exon

Breast cancer (HER2+)

Bosutinib (Bosulif) Brentuximab vedotin

ABL CD30

Mantle cell lymphoma

Chronic myelogenous leukemia (Philadelphia chromosome positive) Hodgkin lymphoma

Anaplastic large cell lymphoma Medullary thyroid cancer

(Adcetris)

Cabozantinib (Cometriq)

VEGFR2

Canakinumab (Ilaris)

Carfilzomib (Kyprolis)

IL-1β Proteasome

Juvenile idiopathic arthritis

Cryopyrin-associated periodic syndromes Multiple myeloma

FLT3, KIT, MET, RET,

Ceritinib (Zykadia) Cetuximab (Erbitux)

Crizotinib (Xalkori) Dabrafenib (Tafinlar) Dasatinib (Sprycel)

Denosumab (Xgeva) Erlotinib (Tarceva)

Everolimus (Afinitor)

Gefitinib (Iressa) Ibritumomab tiuxetan

ALK

EGFR (HER1/ERBB1) ALK, MET BRAF ABL RANKL

EGFR (HER1/ERBB1) mTOR

Non-small cell lung cancer (with ALK fusion) Colorectal cancer (KRAS wild type)

西妥昔单抗注射液

Squamous cell cancer of the head and neck Non-small cell lung cancer (with ALK fusion) Melanoma (with BRAF V600 mutation)

Chronic myelogenous leukemia (Philadelphia chromosome positive) Acute lymphoblastic leukemia (Philadelphia chromosome positive) Giant cell tumor of the bone Non-small cell lung cancer

克唑替尼胶囊

达沙替尼片

盐酸厄洛替尼片

Pancreatic cancer

Pancreatic neuroendocrine tumor Renal cell carcinoma

Nonresectable subependymal giant cell astrocytoma associated with

依维莫司片

tuberous sclerosis

EGFR (HER1/ERBB1)

(limited approval)

CD20

(Zevalin)

Ibrutinib (Imbruvica) |

2014-12-30 11:29jastee

BTK

Mantle cell lymphoma

Non-Hodgkin's lymphoma

Breast cancer (HR+, HER2-)

Non-small cell lung cancer with known prior benefit from gefitinib

吉非替尼片

Idelalisib (Zydelig)

Imatinib (Gleevec)

Ipilimumab (Yervoy) Lapatinib (Tykerb)

PI3Kδ

KIT, PDGFR, ABL

Chronic lymphocytic leukemia Chronic lymphocytic leukemia

Follicular B-cell non-Hodgkin lymphoma Small lymphocytic lymphoma GI stromal tumor (KIT+) Dermatofibrosarcoma protuberans

Multiple hematologic malignancies including Philadelphia

chromosome-positive ALL and CML

CTLA-4

HER2 (ERBB2/neu), EGFR

Breast cancer (HER2+)

(HER1/ERBB1)

Chronic myelogenous leukemia (Philadelphia chromosome

Nilotinib (Tasigna) Obinutuzumab (Gazyva) Ofatumumab (Arzerra,

CD20

HuMax-CD20)

Panitumumab (Vectibix) Pazopanib (Votrient)

EGFR (HER1/ERBB1) VEGFR, PDGFR, KIT

Colorectal cancer (KRAS wild type) Renal cell carcinoma Melanoma

Breast cancer (HER2+)

Chronic lymphocytic leukemia

ABL

positive)

CD20

Chronic lymphocytic leukemia

囊 尼洛替尼胶

Melanoma

Pembrolizumab (Keytruda) PD-1 Pertuzumab (Perjeta)

HER2 (ERBB2/neu)

Ponatinib (Iclusig)

Ramucirumab (Cyramza) ABL, FGFR1-3, FLT3, VEGFR2 Chronic myelogenous leukemia VEGFR2

Acute lymphoblastic leukemia (Philadelphia chromosome positive) Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma

Regorafenib (Stivarga)

Rituximab (Rituxan, Mabthera)

Romidepsin (Istodax)

Ruxolitinib (Jakafi) Siltuximab (Sylvant) Sipuleucel-T (Provenge) Sorafenib (Nexavar)

Temsirolimus (Torisel) Tocilizumab (Actemra)

Tofacitinib (Xeljanz) Tositumomab (Bexxar) Trametinib (Mekinist) Trastuzumab (Herceptin)

Vandetanib (Caprelsa)

Vemurafenib (Zelboraf) Vismodegib (Erivedge) Vorinostat (Zolinza) Ziv-aflibercept (Zaltrap)

KIT, PDGFRβ, RAF, RET,

VEGFR1/2/3 CD20

HDAC JAK1/2 IL-6

VEGFR, PDGFR, KIT, RAF mTOR IL-6R JAK3 CD20 MEK

HER2 (ERBB2/neu)

EGFR (HER1/ERBB1), RET,

VEGFR2

BRAF

PTCH, Smoothened HDAC

PIGF, VEGFA/B

Colorectal cancer

Gastrointestinal stromal tumors Non-Hodgkin’s lymphoma

Chronic lymphocytic leukemia Rheumatoid arthritis

Granulomatosis with polyangiitis Cutaneous T-cell lymphoma Peripheral T-cell lymphoma Myelofibrosis

Multicentric Castleman's disease Prostate cancer

Hepatocellular carcinoma

Renal cell carcinoma Thyroid carcinoma Renal cell carcinoma Rheumatoid arthritis

Juvenile idiopathic arthritis Rheumatoid arthritis Non-Hodgkin's lymphoma

Melanoma (with BRAF V600 mutation) Breast cancer (HER2+)

Gastric cancer (HER2+) Medullary thyroid cancer

Melanoma (with BRAF V600 mutation) Basal cell carcinoma Cutaneous T-cell lymphoma Colorectal cancer

.利妥昔单抗注射液

甲苯磺酸索拉非尼片

托珠单抗注射液

注射用曲妥珠单抗 (

搜索“diyifanwen.net”或“第一范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读,第一范文网,提供最新综合文库对比FDA和CFDA批准的抗癌药物列表 全文阅读和word下载服务。

对比FDA和CFDA批准的抗癌药物列表 .doc 将本文的Word文档下载到电脑,方便复制、编辑、收藏和打印
本文链接:https://www.diyifanwen.net/wenku/1041163.html(转载请注明文章来源)
热门推荐
Copyright © 2018-2022 第一范文网 版权所有 免责声明 | 联系我们
声明 :本网站尊重并保护知识产权,根据《信息网络传播权保护条例》,如果我们转载的作品侵犯了您的权利,请在一个月内通知我们,我们会及时删除。
客服QQ:xxxxxx 邮箱:xxxxxx@qq.com
渝ICP备2023013149号
Top